Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Exelixis
Related studies linked through entity extraction aliases.
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
- Status
- RECRUITING
- Phase
- PHASE3
H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma
- Status
- RECRUITING
- Phase
- PHASE2
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
- Status
- RECRUITING
- Phase
- PHASE3
Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Zanzalintinib in Men With Aggressive Variant Prostate Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)
- Status
- RECRUITING
- Phase
- PHASE2
Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Zanzalintinib for Advanced Urothelial Carcinoma Progressing After Prior Therapy
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma
- Status
- RECRUITING
- Phase
- PHASE1
Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)
- Status
- RECRUITING
- Phase
- PHASE1
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
- Status
- RECRUITING
- Phase
- PHASE2
Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma
- Status
- RECRUITING
- Phase
- PHASE1
A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3